Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | GOT1 | P17174 | 1/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535398 | 0.92 | ALOX5 (0.52) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL7786850 | 0.89 | NPC1 (0.53) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL7786884 | 0.88 | RARA (0.49) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL3807977 | 0.85 | RARA (0.67) | MEN1NR1I2LMNAPGRRARA | |
| SCHEMBL7786848 | 0.83 | LMNA (0.50) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL7786877 | 0.82 | RARA (0.49) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL7786900 | 0.81 | PDE4A (0.53) | ALOX5EPHX2MEN1NR1I2LMNA | |
| SCHEMBL3807973 | 0.79 | RARB (0.67) | MEN1NR1I2LMNAPGRRARA | |
| SCHEMBL13550931 | 0.78 | RARB (0.69) | MEN1NR1I2LMNAPGRRARA | |
| SCHEMBL29869357 | 0.78 | RARB (0.69) | MEN1NR1I2LMNAPGRRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272176-A4 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-29 | — | — | EP | claimed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | claimed |
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-04-17 | — | — | US | claimed |
| EP-1272176-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | Galderma Research & Development, S.N.C. (FR) | 2003-01-08 | — | — | EP | claimed |
| WO-2001056563-A9 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2002-10-31 | — | — | WO | claimed |
| US-6462064-B1 | SUCH AS 6-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-2-NAPHTHOIC ACID, 2-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-5-BENZIMIDAZOLE CARBOXY-LIC ACID, AND 6-(3-(1-ADAMANTYL)-4,5-METHYLENEDIOXYPHENYL)-2-NAPHTHOIC ACID | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-10-08 | — | — | US | claimed |
| WO-2001056563-A1 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-08-09 | — | — | WO | claimed |
| JP-2000515506-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0920312-A4 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2000-11-02 | — | — | EP | claimed |
| US-6127415-A | ADAMANTYL DERIVATIVE CONTAINING-RETINOID RELATED COMPOUNDS AS ANTICARCINOGENIC AGENTS; SKIN DISORDERS;COSMETICS; AGING RESISTANCE; ALOPEIA | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-10-03 | — | — | US | claimed |
| EP-0920312-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | Galderma Research & Development (FR) | 1999-06-09 | — | — | EP | claimed |
| WO-1998001132-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-15 | — | — | WO | claimed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | CASP3, BAD, RARA | ALOX5 857/4885EPHX2 2188/4885MEN1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.